Medindia

X

The FDA Group Hires Industry Expert Brie Stoianoff as Director of Quality & Service Assurance

Tuesday, August 9, 2016 Corporate News J E 4
Advertisement

WESTBOROUGH, Mass., Aug. 9, 2016 /PRNewswire-iReach/ -- Brie Stoianoff has joined The FDA Group in a newly created role as Director of Quality & Service Assurance.  Ms. Stoianoff comes to the company with more than 15 years of experience in the pharmaceutical and medical device industries.  Over her career, she has been able to provide expert advice to tackle the quality and regulatory compliance needs of bioscience companies worldwide.  In addition to her industry experience, she has a Master's Degree in Quality Assurance and Regulatory Affairs from the Temple University School of Pharmacy and she is a Certified Quality Auditor (CQA) and a Certified Quality Engineer (CQE) by the American Society for Quality.

Photo - http://photos.prnewswire.com/prnh/20160808/396420

For the past two years, she successfully led Vision 28 LLC as the President & CEO.  Prior to Vision 28, she held Director of Quality and Regulatory roles at Acumed and CompView Medical.  She also spent time at Welch Allyn, AstraZeneca, Shire, and DuPont Pharmaceutical Company (now Bristol-Myers Squibb.)

More about The FDA Group

The FDA Group is a global leader in GxP auditing & remediation and regulatory services.  Their purpose is to empower our clients to bring their life-changing healthcare products to the market and keep them there.

The FDA Group is able to do this by providing a world-class service experience. The way in which The FDA Group ensures a world-class service experience is by its proprietary talent selection process coupled with its deep-rooted corporate culture that includes 31 Fundamentals.  These Fundamentals are the heart-beat of the organization and are focused on four areas: Core Values, Focus on Service, The Collaborative Way, and Personal Effectiveness.

For more information, contact:

Andrea Houlne(508) 926-8330info@thefdagroup.com

Media Contact: Andrea Houlne, The FDA Group, 508-926-8330, ahoulne@thefdagroup.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE The FDA Group

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
New Joint Health Chewable Supplement From Valensa
S
Pathology Labs Seeking Compact Solution to Quality...